Konstantinos C. Koskinas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Konstantinos C. Koskinas has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
Stephan Windecker
Department of Cardiology, Bern University Hospital-INSELSPITAL, University of Bern, Bern, Switzerland
6 shared publicationsLorenz Räber
Department of Cardiology, University Hospital Bern , Switzerland
5 shared publications- Lorenz Räber
Department of Cardiology, Bern University Hospital, Inselspital, University of Bern
5 shared publications Dik Heg
CTU Bern, University of Bern, Bern, Switzerland
4 shared publicationsFrançois Mach
Division of Cardiology, Geneva University Hospital , Switzerland
3 shared publications- François Mach
Cardiology Department, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland
3 shared publications
Latest Publications
- 1 July 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (7)
Efficacy of the Shear Stress Pattern Computed in Coronary Artery Reconstruction Models With and Without Side Branches in Predicting Plaque Progression
BACKGROUND: The incorporation of side branches in vessel geometry influences wall shear stress (WSS) distribution. However, complete vessel reconstruction is time-consuming, and there is no evidence that its WSS estimations better predict atherosclerotic disease progression compared with the output of the conventional single-vessel reconstruction (SVR). METHODS: Patients who had baseline and 1-year follow-up intravascular ultrasound imaging (n=40 vessels), and patients with neoatherosclerotic lesions (n=13 vessels) on optical coherence tomography were included. All the studied vessels had at least one side branch with a diameter >1 mm; 3-dimensional complete vessel reconstruction and SVR were performed, and the time-averaged WSS and multidirectional WSS were computed. The performance of both methods in predicting disease progression in intravascular ultrasound and optical coherence tomography models was assessed. RESULTS: The incorporation of side branches in 3-dimensional geometry resulted in lower minimum predominant time-averaged WSS in the intravascular ultrasound (1.09 versus 1.58 Pa, P P <0.001) and influenced the multidirectional WSS distribution. In native segments, complete vessel reconstruction–derived WSS metrics demonstrated superior predictive performance for disease progression—defined as lumen area reduction and plaque burden increase—compared with SVR, as evidenced by improved out-of-sample accuracy (leave-one-out information criterion: 429 versus 551), discrimination (C statistic: 0.725 versus 0.651), calibration (Brier score: 0.172 versus 0.226), and explained variance (27.8% versus 20.7%). Consistent findings were observed in stented segments, where complete vessel reconstruction–derived WSS metrics more accurately predicted neointimal proliferation than SVR-derived metrics. CONCLUSIONS: Incorporating side branches into vessel reconstruction influences WSS distribution and enables more accurate prediction of atherosclerotic disease progression in native and stented segments than SVR.
- 1 July 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (7)
Efficacy of the Shear Stress Pattern Computed in Coronary Artery Reconstruction Models With and Without Side Branches in Predicting Plaque Progression
BACKGROUND: The incorporation of side branches in vessel geometry influences wall shear stress (WSS) distribution. However, complete vessel reconstruction is time-consuming, and there is no evidence that its WSS estimations better predict atherosclerotic disease progression compared with the output of the conventional single-vessel reconstruction (SVR). METHODS: Patients who had baseline and 1-year follow-up intravascular ultrasound imaging (n=40 vessels), and patients with neoatherosclerotic lesions (n=13 vessels) on optical coherence tomography were included. All the studied vessels had at least one side branch with a diameter >1 mm; 3-dimensional complete vessel reconstruction and SVR were performed, and the time-averaged WSS and multidirectional WSS were computed. The performance of both methods in predicting disease progression in intravascular ultrasound and optical coherence tomography models was assessed. RESULTS: The incorporation of side branches in 3-dimensional geometry resulted in lower minimum predominant time-averaged WSS in the intravascular ultrasound (1.09 versus 1.58 Pa, P P <0.001) and influenced the multidirectional WSS distribution. In native segments, complete vessel reconstruction–derived WSS metrics demonstrated superior predictive performance for disease progression—defined as lumen area reduction and plaque burden increase—compared with SVR, as evidenced by improved out-of-sample accuracy (leave-one-out information criterion: 429 versus 551), discrimination (C statistic: 0.725 versus 0.651), calibration (Brier score: 0.172 versus 0.226), and explained variance (27.8% versus 20.7%). Consistent findings were observed in stented segments, where complete vessel reconstruction–derived WSS metrics more accurately predicted neointimal proliferation than SVR-derived metrics. CONCLUSIONS: Incorporating side branches into vessel reconstruction influences WSS distribution and enables more accurate prediction of atherosclerotic disease progression in native and stented segments than SVR.
- 16 June 2026
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (8) , 967-969
Coronary CT Angiography
- 16 June 2026
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (8) , 967-969
Coronary CT Angiography
- 2 April 2026
- Published by Elsevier in Atherosclerosis
- Vol. 415, 120703
Erratum to “2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias” [Atherosclerosis, 409, (October 2025), 120479]
- 2 April 2026
- Published by Elsevier in Atherosclerosis
- Vol. 415, 120703
Erratum to “2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias” [Atherosclerosis, 409, (October 2025), 120479]
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e005345
Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins
BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition is a potent cholesterol-lowering strategy. This study examined the effects of PCSK9 monoclonal antibodies (mAbs) and high-intensity statins beyond low-density lipoprotein cholesterol reduction, which are not fully defined, particularly in patients with acute myocardial infarction (MI). METHODS: Proteomic and lipidomic analyses were conducted on plasma from 265 patients with acute MI from the PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) randomized, placebo-controlled PCSK9 mAb trial and 34 patients without MI with hyperlipidemia from the Vienna Lipid Clinic registry, also receiving PCSK9 mAbs. RESULTS: Discovery proteomics revealed changes in apolipoproteins and increased PCOLCE (procollagen C-endopeptidase enhancer 1) levels in both the PCSK9 mAb and placebo groups after MI. UK Biobank data confirmed PCOLCE and PCSK9 upregulation as associated with statin use. Hepatoma cell experiments demonstrated a dose-dependent PCOLCE induction on statin treatment. Compared with placebo (statins only), PCSK9 mAb therapy resulted in greater reductions in APOB (apolipoprotein B), APOE (apolipoprotein E), APOC2 (apolipoprotein C2), and APOC3 (apolipoprotein C3), as shown by targeted proteomics. Mediation analysis indicated that these changes were largely explained by low-density lipoprotein cholesterol lowering. Lipidomics identified more pronounced reductions in cholesteryl esters, ceramides, sphingomyelins, phosphatidylcholines, triglycerides, and diglycerides in PCSK9 mAb-treated patients with MI. Results were largely consistent in patients without MI. However, levels of LPA (apolipoprotein[a]), the characteristic protein component of lipoprotein(a), remained unchanged in PCSK9 mAb-treated patients with MI, since a rise of LPA was observed in the placebo group post-MI. CONCLUSIONS: Most apolipoprotein changes after PCSK9 mAb therapy following MI were mediated by low-density lipoprotein cholesterol lowering. Statin use is associated with increased circulating PCOLCE, with hepatoma cell experiments supporting a predominant hepatic origin. Combining PCSK9 mAbs with high-intensity statins mitigates post-MI increases in lipoprotein(a). REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03067844.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e005345
Open AccessIntegrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins
BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition is a potent cholesterol-lowering strategy. This study examined the effects of PCSK9 monoclonal antibodies (mAbs) and high-intensity statins beyond low-density lipoprotein cholesterol reduction, which are not fully defined, particularly in patients with acute myocardial infarction (MI). METHODS: Proteomic and lipidomic analyses were conducted on plasma from 265 patients with acute MI from the PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) randomized, placebo-controlled PCSK9 mAb trial and 34 patients without MI with hyperlipidemia from the Vienna Lipid Clinic registry, also receiving PCSK9 mAbs. RESULTS: Discovery proteomics revealed changes in apolipoproteins and increased PCOLCE (procollagen C-endopeptidase enhancer 1) levels in both the PCSK9 mAb and placebo groups after MI. UK Biobank data confirmed PCOLCE and PCSK9 upregulation as associated with statin use. Hepatoma cell experiments demonstrated a dose-dependent PCOLCE induction on statin treatment. Compared with placebo (statins only), PCSK9 mAb therapy resulted in greater reductions in APOB (apolipoprotein B), APOE (apolipoprotein E), APOC2 (apolipoprotein C2), and APOC3 (apolipoprotein C3), as shown by targeted proteomics. Mediation analysis indicated that these changes were largely explained by low-density lipoprotein cholesterol lowering. Lipidomics identified more pronounced reductions in cholesteryl esters, ceramides, sphingomyelins, phosphatidylcholines, triglycerides, and diglycerides in PCSK9 mAb-treated patients with MI. Results were largely consistent in patients without MI. However, levels of LPA (apolipoprotein[a]), the characteristic protein component of lipoprotein(a), remained unchanged in PCSK9 mAb-treated patients with MI, since a rise of LPA was observed in the placebo group post-MI. CONCLUSIONS: Most apolipoprotein changes after PCSK9 mAb therapy following MI were mediated by low-density lipoprotein cholesterol lowering. Statin use is associated with increased circulating PCOLCE, with hepatoma cell experiments supporting a predominant hepatic origin. Combining PCSK9 mAbs with high-intensity statins mitigates post-MI increases in lipoprotein(a). REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03067844.
- Top Cited Papers
- 19 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (6) , 658-659
The ‘10 commandments’ for the 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias
- 19 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (6) , 658-659
Top Cited PapersThe ‘10 commandments’ for the 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias
- 18 March 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2593-2594
Visceral adiposity by computed tomography imaging and cardiovascular risk: seeing is believing
- 18 March 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2593-2594
Visceral adiposity by computed tomography imaging and cardiovascular risk: seeing is believing
- 21 February 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (13) , 1190-1191
Remnant cholesterol for cardiovascular risk assessment in the young: ready for prime time?
- 21 February 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (13) , 1190-1191
Remnant cholesterol for cardiovascular risk assessment in the young: ready for prime time?
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (2) , e017965
Response to Letter Regarding Article, “Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab”
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (2) , e017965
Response to Letter Regarding Article, “Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab”
- 1 November 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (11) , e016683
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab
BACKGROUND: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy. METHODS: In the PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction), 300 patients with acute myocardial infarction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensity statins. Patients underwent serial 2-vessel intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy in the non–infarct-related arteries at baseline and after 52 weeks. The main end points were percent atheroma volume by intravascular ultrasound, minimum fibrous cap thickness by optical coherence tomography, and maximum lipid core burden index within 4 mm (maxLCBI 4mm ) by near-infrared spectroscopy. RESULTS: A total of 265 patients had serial intravascular ultrasound data (mean age, 58±9 years; 16% women). Alirocumab resulted in greater reductions in percent atheroma volume and maxLCBI 4mm , as well as a greater increase in minimum fibrous cap thickness, compared with placebo. In the alirocumab group, the reduction in maxLCBI 4mm was smaller in patients with higher baseline Lp(a), defined by the highest quartile (Q4, ≥98 nmol/L; n=30), than in those with lower baseline Lp(a) (Q1–Q3, P =0.01 after adjustment for clinically relevant baseline variables), and was comparable to the maxLBI 4mm reduction in the placebo group (−37.60 [−57.40 to −17.80]; n=134). These findings were consistent when higher baseline Lp(a) was defined by cut-off values of ≥75 versus <75 nmol/L (n=35 versus 94, respectively, in the alirocumab group) and ≥125 versus <125 nmol/L (n=23 versus 106, respectively). Changes in percent atheroma volume and minimum fibrous cap thickness did not differ in relation to baseline Lp(a). CONCLUSIONS: In patients with acute myocardial infarction, elevated Lp(a) at baseline is associated with attenuation of plaque lipid regression despite intensive treatment with alirocumab plus high-intensity statin. This finding may explain the residual cardiovascular risk associated with high Lp(a) despite optimal control of lipid levels. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03067844.
- 1 November 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (11) , e016683
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab
BACKGROUND: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy. METHODS: In the PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction), 300 patients with acute myocardial infarction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensity statins. Patients underwent serial 2-vessel intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy in the non–infarct-related arteries at baseline and after 52 weeks. The main end points were percent atheroma volume by intravascular ultrasound, minimum fibrous cap thickness by optical coherence tomography, and maximum lipid core burden index within 4 mm (maxLCBI 4mm ) by near-infrared spectroscopy. RESULTS: A total of 265 patients had serial intravascular ultrasound data (mean age, 58±9 years; 16% women). Alirocumab resulted in greater reductions in percent atheroma volume and maxLCBI 4mm , as well as a greater increase in minimum fibrous cap thickness, compared with placebo. In the alirocumab group, the reduction in maxLCBI 4mm was smaller in patients with higher baseline Lp(a), defined by the highest quartile (Q4, ≥98 nmol/L; n=30), than in those with lower baseline Lp(a) (Q1–Q3, P =0.01 after adjustment for clinically relevant baseline variables), and was comparable to the maxLBI 4mm reduction in the placebo group (−37.60 [−57.40 to −17.80]; n=134). These findings were consistent when higher baseline Lp(a) was defined by cut-off values of ≥75 versus <75 nmol/L (n=35 versus 94, respectively, in the alirocumab group) and ≥125 versus <125 nmol/L (n=23 versus 106, respectively). Changes in percent atheroma volume and minimum fibrous cap thickness did not differ in relation to baseline Lp(a). CONCLUSIONS: In patients with acute myocardial infarction, elevated Lp(a) at baseline is associated with attenuation of plaque lipid regression despite intensive treatment with alirocumab plus high-intensity statin. This finding may explain the residual cardiovascular risk associated with high Lp(a) despite optimal control of lipid levels. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03067844.